SAARC Consensus Recommendations for the diagnosis and treatment of non-small-cell lung cancer (NSCLC)

This publication has 108 references indexed in Scilit:

• 1258MO Low dose versus standard dose pembrolizumab for treatment of stage IV stage non-small cell lung carcinoma: Results of the pre-planned interim analysis of the NVALT-30 clinical trial
  Annals of Oncology, 2024
• Gefitinib vs Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Variant Lung Cancer—Long-Term Results of a Randomized Clinical Trial
  JAMA Oncology, 2024
• Proton therapy in Asia Pacific: current resources, international disparities and steps forward
  Journal of Medical Radiation Sciences, 2024
• 1384P Phase II study of cabozantinib in patients with MET-altered lung cancers
  Annals of Oncology, 2023
• Surgery for lung cancer: insight from a state cancer centre in India
  Indian Journal of Thoracic and Cardiovascular Surgery, 2023
• Improving the performance status in advanced non-small cell lung cancer patients with chemotherapy (ImPACt trial): a phase 2 study
  Journal of Cancer Research and Clinical Oncology, 2023
• KRAS mutated Non‐Small Lung Carcinoma: A Real World Context from the Indian subcontinent
  Cancer Medicine, 2022
• Low‐dose pembrolizumab in the treatment of advanced non‐small cell lung cancer
  International Journal of Cancer, 2021
• Low-Dose Erlotinib Treatment in Elderly or Frail Patients With EGFR Mutation–Positive Non–Small Cell Lung Cancer
  JAMA Oncology, 2020
• A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III non-small-cell lung cancer (NSCLC): a Galician Lung Cancer Group (GGCP) study
  Cancer Chemotherapy and Pharmacology, 2013